Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 381

Sort by

Sort Order Select

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Journal Articles

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Alissa Visram, Dirk Larson, Aaron Norman, Angela Dispenzieri, David Murray, Robert Kyle, S. Vincent Rajkumar, Susan Slager, Shaji Kumar, Celine Vachon

Blood (2025) 145 (3): 325–333.

https://doi.org/10.1182/blood.2024025415

Published: 2025

Includes: Supplemental data

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri, Sagar Lonial, Brian G. M. Durie, Paul G. Richardson, Saad Z. Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2025) 145 (1): 75–84.

https://doi.org/10.1182/blood.2024025939

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Immunomodulatory Effects of MEK Inhibition in Multiple Myeloma

Chaitanya Acharya, Reyka G. Jayasinghe, Mark Hamilton, Sacha Gnjatic, Seunghee Kim-Schulze, Hearn Jay Cho, Shaji Kumar, George Mulligan

Blood (2024) 144 (Supplement 1): 6863.

https://doi.org/10.1182/blood-2024-210989

Published: 2024

Journal Articles

Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

Blood (2024) 144 (Supplement 1): 2400.

https://doi.org/10.1182/blood-2024-209102

Published: 2024

Journal Articles

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2024-203892

Published: 2024

Journal Articles

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2372.

https://doi.org/10.1182/blood-2024-210474

Published: 2024

Journal Articles

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Betty Gration, Bradley Augustson, Peter Mollee, Jennifer Zhang, Nicole Wong Doo, Sabine Ringkowski, Adam Bryant, Slavisa Ninkovic, Nada Hamad, Georgia McCaughan, Shaji Kumar, Andrew Spencer, Hang Quach

Blood (2024) 144 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2024-207609

Published: 2024

Journal Articles

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Arwa Bohra, Surendra Dasari, Wilson I. Gonsalves, Prashant Kapoor, Saurabh Zanwar, Moritz Binder, Angela Dispenzieri, Michael M Timm, Dragan Jevremovic, S. Vincent Rajkumar, Shaji Kumar

Blood (2024) 144 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2024-211902

Published: 2024

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Blood (2024) 144 (Supplement 1): 7039.

https://doi.org/10.1182/blood-2024-210376

Published: 2024

Journal Articles

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 7589.

https://doi.org/10.1182/blood-2024-210586

Published: 2024

Journal Articles

Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis

Anand Pabmanabhan, Noah Splinter, Emily Mauch, Adam Kanack, Rajiv K Pruthi, Dong Chen, Angela Dispenzieri, Shaji Kumar, Damon E. Houghton

Blood (2024) 144 (Supplement 1): 3996.

https://doi.org/10.1182/blood-2024-207999

Published: 2024

Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau

Blood (2024) 144 (Supplement 1): 4757.1.

https://doi.org/10.1182/blood-2024-199752

Published: 2024

Journal Articles

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Blood (2024) 144 (Supplement 1): 4685.1.

https://doi.org/10.1182/blood-2024-208457

Published: 2024

Journal Articles

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Rahul Banerjee, Amber R. Fritz, Othman S. Akhtar, Ciara Louise Freeman, Andrew J. Cowan, Nina Shah, Heather J. Landau, Shaji Kumar, Dan T. Vogl, Yvonne A. Efebera, Philip L. McCarthy, David H. Vesole, Adam Mendizabal, Amrita Y Krishnan, George Somlo, Edward A. Stadtmauer, Marcelo C. Pasquini

Blood (2024) 144 (Supplement 1): 81.

https://doi.org/10.1182/blood-2024-199615

Published: 2024

Journal Articles

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Nadia Toumeh, Matthew James Rees, Morie A. Gertz, Angela Dispenzieri, Binoy Yohannan, Suheil Albert Atallah-Yunes, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Suzanne R Hayman, Francis Buadi, David Dingli, Joselle Cook, Rahma M Warsame, Moritz Binder, Wilson I. Gonsalves, S. Vincent Rajkumar, Shaji Kumar, Eli Muchtar

Blood (2024) 144 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2024-202059

Published: 2024

Journal Articles

Proteomic Determinants of Renal Organ Response in AL Amyloidosis

Matthew James Rees, Eli Muchtar, Suheil Albert Atallah-Yunes, Surendra Dasari, Nelson Leung, Morie A. Gertz, Angela Dispenzieri, Ellen McPhail, Shaji Kumar, Emilie Anderson, Christopher Dick, Taxiarchis Kourelis

Blood (2024) 144 (Supplement 1): 3305.

https://doi.org/10.1182/blood-2024-201168

Published: 2024

Journal Articles

MGUS Prevalence in Special Populations: Insights from a Large-Scale Community Study from Rural India (IMAGe-002B Study)

Uday Yanamandra, Harikrishnan Premdeep, J Muthukrishnan, Narendra Kotwal, Pankaj Malhotra, Velu Nair, Shaji Kumar

Blood (2024) 144 (Supplement 1): 1916.

https://doi.org/10.1182/blood-2024-210555

Published: 2024

Journal Articles

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Blood (2024) 144 (Supplement 1): 3792.5.

https://doi.org/10.1182/blood-2024-210957

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Immunomodulatory Effects of MEK Inhibition in Multiple Myeloma

Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Development of a Three-Gene-Based Proliferation Score (3GPS) to Predict Proliferation Index in Newly Diagnosed Multiple Myeloma

Comparative Effectiveness of Linvoseltamab Versus Current Real-World Standard of Care Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated at IMWG Sites

Prescriber Preference in Treatment of Relapsed or Refractory Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL)

Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis

Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients

Proteomic Determinants of Renal Organ Response in AL Amyloidosis

MGUS Prevalence in Special Populations: Insights from a Large-Scale Community Study from Rural India (IMAGe-002B Study)

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only